This company has been acquired
LOGC Stock Overview
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LogicBio Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.07 |
| 52 Week High | US$3.63 |
| 52 Week Low | US$0.26 |
| Beta | 4.62 |
| 1 Month Change | 0.98% |
| 3 Month Change | 417.63% |
| 1 Year Change | -40.35% |
| 3 Year Change | -76.79% |
| 5 Year Change | n/a |
| Change since IPO | -82.00% |
Recent News & Updates
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Shareholder Returns
| LOGC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.5% | -1.8% | -3.1% |
| 1Y | -40.3% | 10.3% | 15.1% |
Return vs Industry: LOGC underperformed the US Biotechs industry which returned -15.1% over the past year.
Return vs Market: LOGC underperformed the US Market which returned -21.9% over the past year.
Price Volatility
| LOGC volatility | |
|---|---|
| LOGC Average Weekly Movement | 179.9% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: LOGC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 80% a day.
Volatility Over Time: LOGC's weekly volatility has increased from 92% to 180% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 62 | Fred Chereau | https://www.logicbio.com |
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company’s GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.
LogicBio Therapeutics, Inc. Fundamentals Summary
| LOGC fundamental statistics | |
|---|---|
| Market Cap | US$68.23m |
| Earnings (TTM) | -US$26.54m |
| Revenue (TTM) | US$10.76m |
6.3x
P/S Ratio-2.6x
P/E RatioIs LOGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LOGC income statement (TTM) | |
|---|---|
| Revenue | US$10.76m |
| Cost of Revenue | US$30.68m |
| Gross Profit | -US$19.92m |
| Other Expenses | US$6.62m |
| Earnings | -US$26.54m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | -185.15% |
| Net Profit Margin | -246.71% |
| Debt/Equity Ratio | 37.7% |
How did LOGC perform over the long term?
See historical performance and comparison